LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

Sector Healthcare

7.99 -1.11

Buy Sell

Overview

Share price change

24h

Current

Min

7.98

Max

8.05

Key metrics
By Trading Economics
EPS	-0.172
Profit margin	-66.092
Employees	536

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+92.11 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	41M 990M
Previous open	9.1
Previous close	7.99

News Sentiment

By Acuity

67%

33%

308 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

6.1 / 7.65 Support & Resistance

BioCryst Pharmaceuticals Inc Chart

Related News

6 Sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 Sept 2024, 21:18 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 Sept 2024, 21:05 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 Sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 Sept 2024, 20:39 UTC

Earnings

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 Sept 2024, 20:35 UTC

Top News

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 Sept 2024, 20:34 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 Sept 2024, 20:11 UTC

Top News

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 Sept 2024, 19:51 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 Sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 Sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 Sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 Sept 2024, 18:27 UTC

Top News

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 Sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 Sept 2024, 18:15 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 Sept 2024, 18:12 UTC

Top News

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 Sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 Sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 Sept 2024, 17:30 UTC

Top News

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 Sept 2024, 17:27 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 Sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 Sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 Sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 Sept 2024, 16:35 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 Sept 2024, 16:33 UTC

Acquisitions, Mergers, Takeovers

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 Sept 2024, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Earnings

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 Sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

92.11% upside

12 Months Forecast

Average 15.33 USD 92.11%

High 30 USD

Low 7 USD

Based on 9 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.1 / 7.65Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

308 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.